CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 333 enrolled
Drug / intervention
TRV130 +2 moredrug
Likely dose
TRV130 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02100748
NCT02100748Phase 2Completed

A Phase 2, Multicenter, Randomized, Double-blind, Multiple-dose, Adaptive, Placebo- and Active-controlled Study of TRV130 for the Treatment of Acute Postoperative Pain After Bunionectomy

Trevena Inc.·interventional·Posted Apr 1, 2014·Updated Sep 16, 2020

In Brief

A Phase 2 clinical trial evaluating TRV130, Morphine, and 1 other intervention for Acute Pain. Completed, enrolled 333 participants across 4 sites.

Detailed Summary

The primary objective is to evaluate the analgesic efficacy of IV TRV130 compared with placebo in patients with acute postoperative pain after bunionectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Pain
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 1, 2014
Enrollment StartApr 1, 2014
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.3 years ago

Interventions

TRV130drug

TRV130 1 - 4 mg will be administered every 4 hours

Morphinedrug

Morphine 4 mg will be administered every 4 hours

Placebodrug

Placebo will be administered every 4 hours